U.S. FDA advisory panel to meet on COVID-19 vaccines in children
Reuters
Published May 10, 2021 12:30PM ET
Updated May 10, 2021 12:47PM ET
(Reuters) -The U.S. Food and Drug Administration said on Monday it will hold a meeting of its independent panel of advisers on June 10 to discuss the use of COVID-19 vaccines in children.
The committee will not discuss any specific products, the agency said. FDA spokesperson Stephanie Caccomo said the meeting has nothing to do with Pfizer Inc (NYSE:PFE) and BioNTech SA's request to expand the U.S. Emergency Use Authorization (EUA) of their vaccine into younger children.
That vaccine is currently authorized for use in people 16 or older in the United States. The vaccine makers have asked to expand that authorization to children as young as 12, and Pfizer said last week it expects the FDA response soon.
The FDA said last month it did not plan to hold an advisory committee meeting for the Pfizer-BioNTech expansion.
"As with the initial COVID-19 vaccine authorizations, we want to ensure that the public has a clear understanding of our expectations for the data and information needed to support requests for emergency use authorization and biologics license applications for vaccines intended to prevent COVID-19 in this pediatric age range," Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.
(Reporting Kalluvilaby Manojna Maddipatla in Bengaluru and Michael Erman in New York; Editing by Sriraj)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.